Lennard is one of our high skilled clinical academics, whose expertise lies in his successful delivery of national research programmes. These lever his growing experience, insight and capabilities in national project management, skills he has been honing since 2020.

His skillsets are in aligning the needs of scientists, national leads, clinicians and patients and ultimately pushing the boundaries nationally of what was previously perceived as possible.

As a lead on the UK's cancer vaccine initiative, Lennard spearheads a comprehensive strategy aiming to propel global advancements in cancer vaccines, initiate trials across various cancer stages and subtypes, and enroll 10,000 patients in clinical trials by 2030. His efforts include founding and facilitating the NHS Cancer Vaccine Launchpad, a national system designed to streamline patient enrollment in cancer vaccine trials, and maintaining momentum to deliver through national events and meetings. Collaborating closely with UK government officials, Lennard plays a critical role in connecting the clinical community with emerging technological opportunities, ensuring the most efficient process to clinical impact.

For his work, Lennard has received numerous accolades, including the National ACP McElwain Prize, the IAP outstanding young physicians award and the Department of Science Innovation and Technology Superhero Award. With over 50 publications in top-tier journals and coverage by major media outlets, Lennard continues to empower those involved in cancer care, science, and research, driving innovation and delivering real-world results.

Lennard's modus operandi is to empower those involved in cancer care, science and research. Through openness, acting with the highest level of integrity and humility, the aspiration is that large groups of people could align around strategic projects, building momentum and ultimately lay the path for project successes. Lennard is dedicated to utilise these approaches to partner and drive innovation, accelerate scientific developments and ultimately deliver real world results for those affected by cancer.

His work and research have been covered by the BBC, ITV, Daily Mail, Tortoise Media, and international news outlets. He is an excellent communicator, as illustrated in his role in IndieSAGE. He is incredibly positive and enthusiastic in forming bridges between academics, industry, patients, government and health system.

In addition to his work on cancer vaccines, Lennard has made significant contributions to other high-impact national projects. As the founder of the UK COVID Cancer Programme, he developed a unique population-scale initiative that safeguarded cancer patients globally during the pandemic. This linked the data from 90 hospitals. Within the UK Moonshot initiative, he successfully scaled up lateral flow coronavirus diagnostics across the nation. In his NHS role, he led the record-breaking NHS-Galleri trial, embedding it into 70 hospitals and randomizing 140,000 patients in just 10.2 months to assess a new blood test for 50 types of cancer.